for prolonged release dosage forms. A list indicates the study conditions for immediate release oral dosage forms (5) .
The RDC n.37/2011 also specifies the conditions under which biowaivers could be granted and it includes a section of biowaiver based on Biopharmaceutical Classification System (BCS) (4) . Although the criteria for establishing the high solubility and the high permeability of a substance are similar to those of HC and EMA, Brazilian jurisdiction differs from them in that the biowaiver candidates are determined by the regulatory agency, and a list of those candidates is released and updated periodically. The list is comprised of drugs that exhibit an absorbed fraction of ≥85% (based on reliable investigations in human) and an absence of reported bioinequivalence that had not been detected by in vitro studies performed under BCS conditions (6) . The submitted applications for BCS-based biowaiver should enclose documents that confirm the high solubility of the drug and the similarity of dissolution profiles of the test and reference drug products, which should be rapid or very rapid dissolving (4) . The solubility test should be performed by shake-flask or phase diagram methods, at pH values of 1.2, 4.5, and 6.8 at 37±1°C. The dissolution profiles should be obtained in 900 ml of dissolution media at pH 1.2, 4.5, and 6.8 at 37±1°C, using paddle or basket speeds of 50 and 100 rpm, respectively. The use of surfactants is prohibited, and enzymes are allowed for gelatin capsules only. At least 12 units of each product should be tested. The profile comparison should be done by f2 metric. A dosage form is considered as rapidly or very rapidly dissolving if ≥85% is dissolved in 30 and 15 min, respectively (7) .
Concerning the formulation composition for biowaiver of oral dosage forms, the test drug product should preferably use the same excipients as the reference drug product, but other excipients that are well established for the dosage form, administration route, and drug substance in usual amounts are allowed (4) . Excipients known to affect the bioavailability should be qualitatively the same in the test and reference formulations. Parenteral aqueous solutions do not have to be formulated with the same inactive ingredients as their reference formulations. However, in the case of parenteral oily solutions, the type of oil used as a vehicle has to be qualitatively the same.
It is important to highlight that only BE studies conducted by certified contract research organizations (CROs) are accepted to support the registration of a generic drug product. A list of such certified CROs could be found at ANVISA's website. Other regulatory guidances that should be followed for the establishment of BE are the following: RE n.898/2003, which is the guideline for BE statistics (8); RDC n.27/2012, which is the guideline for bioanalytical method validation (9); and RDC n.103/2003, which defines the requirements for the CRO certification (10) .
